Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717535 | 1.00 | PARP1 (0.59) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL18954101 | 0.82 | PARP1 (0.56) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL30013911 | 0.82 | PARP1 (0.56) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL30353912 | 0.78 | PARP1 (0.44) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL30988805 | 0.78 | PARP1 (0.51) | PARP1IP6K1PDPK1CHEK1SMN1; SMN2 | |
| SCHEMBL25151125 | 0.78 | PARP1 (0.51) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL2798284 | 0.78 | PARP1 (0.51) | PARP1IP6K1PDPK1CHEK1SMN1; SMN2 | |
| SCHEMBL15710544 | 0.78 | PARP1 (0.44) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| Hydrochloric Acid SCHEMBL28100847 | 0.77 | PARP1 (0.43) | PARP1IP6K1PDPK1IP6K3CHEK1 | |
| SCHEMBL20547006 | 0.76 | PARP1 (0.42) | PARP1IP6K1PDPK1IP6K3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024059169-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-110573505-B | C 5 -anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3615522-B1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| WO-2004056812-A1 | 4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056801-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004043472-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PARP1 1226/4885IP6K1 1013/4885PDPK1 640/4885 |
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PARP1 31/4885IP6K1 219/4885PDPK1 59/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PARP1 31/4885IP6K1 219/4885PDPK1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.